GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

GSK plcNYSE: GSK

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of £3.47B rose 71.2% year over year, ahead of the +31.8% change in trailing-twelve-month research & development. Sequentially, it rose 104.8% from the prior quarter. Over 3 fiscal years it compounded at +11.1% a year.

Context

  • Research & development amounted to 23.0% of revenue in FY2025, up 2.6 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +71.2% holds above the trailing-twelve-month pace of +31.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
£3.47B+104.8% QoQ
Last fiscal yearDec 2025
£7.53B+17.6% YoY
LTMJun 2026
£9.2B+31.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+71.2%——
1 year+17.6%——
3-year CAGR+11.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

GBP · from the income statement

Latest · FY2025
7.53B GBP
Year-over-year change
+17.6%
4-year CAGR
+10.7%

Research & Development vs competitors

How GSK compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +31.8% is the 2nd highest of 10, against a peer median of +9.2%.
  • Research & development amounts to 27.7% of revenue for GSK, versus a peer median of 18.3%.
GSK Competitors
Research & Development for GSK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 58.11B DKK+28.3%+29.3%17.6%
MRKMerck & Co., Inc.LTM Jun 2026$28.35B USD+65.7%-2.6%42.7%
JNJJohnson & JohnsonLTM Sep 2026$16.08B USD+2.4%+1.2%16.2%
AZNAstraZeneca PLCLTM Sep 2026$15.01B USD-0.3%+13.4%24.1%
LLYEli Lilly and CompanyLTM Jun 2026$14.6B USD+23.4%+22.9%18.3%
NVSNovartis AGLTM Jun 2026$11.28B USD+9.2%+5.4%20.3%
PFEPfizer Inc.LTM Jun 2026$11.05B USD+7.0%-3.0%17.3%
GSKGSK plcLTM Jun 2026£9.2B GBP+31.8%+11.1%27.7%
SNYSanofiLTM Jun 2026€8.11B EUR+5.4%+6.5%16.6%
AMGNAmgen Inc.LTM Jun 2026$7.64B USD+19.3%+16.3%20.0%
Peer median (excluding GSK) —+9.2%+6.5%18.3%

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue24.7B29.32B30.33B31.38B32.67B
Cost of Revenue8.16B9.55B8.57B9.05B9.02B
Gross Profit16.53B19.77B21.76B22.33B23.65B
Gross Margin66.9%67.4%71.8%71.2%72.4%
Research & Development5.02B5.49B6.22B6.4B7.53B
Selling, General & Admin7.07B8.37B9.39B11.02B9.09B
Operating Expenses12.18B13.34B15.02B18.31B15.31B
Depreciation & Amortization2.12B2.15B2.29B2.55B2.31B
EBITDA6.49B8.6B9.08B6.67B10.4B
EBITDA Margin26.3%29.3%29.9%21.3%31.8%
Operating Income4.36B6.43B6.75B4.02B8.34B
Operating Margin17.6%21.9%22.2%12.8%25.5%
Interest Income28M64.27M40M67.39M56M
Interest Expense784M855.53M775M657.58M687M
Other Income / Expenses(758M)(805M)(681M)(544M)(937M)
Income Before Tax3.6B5.63B6.06B3.48B7.4B
Pre-Tax Margin14.6%19.2%20.0%11.1%22.7%
Income Tax Expense83M707M756M526M1.11B
Net Income4.39B14.96B4.93B2.58B5.72B
Net Margin17.8%51.0%16.2%8.2%17.5%
EPS (Basic)2.747.442.441.262.82
EPS (Diluted)2.707.322.401.242.78
Weighted Avg Shares1.6B2.01B2.03B2.04B2.03B
Weighted Avg Shares (Diluted)1.62B2.04B2.06B2.07B2.06B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.